Cardiac Autonomic Neuropathy in Diabetes Mellitus Patients – Are We Aware of the Consequences?

1. Edwards JL, Vicent AM, Cheng HT et al. Diabetic neuropathy: mechanism to management. Pharmacol Ther 2008; 120: 1-34.10.1016/j.pharmthera.2008.05.005Search in Google Scholar

2. Kempler P. Cardiac autonomic neuropathy: Is it a cardiovascular risk factor in type 2 diabetes? In: Hâncu N [Ed]. Cardiovascular Risk in Type 2 Diabetes Mellitus: assessment and control, Springer-Verlag, Berlin Heidelberg 2003:181-192.10.1007/978-3-642-59352-9_16Search in Google Scholar

3. DCCT Research Group. The effect of intensive diabetes therapy on measures of autonomic nervous system function in the Diabetes Control and Complications Trial (DCCT). Diabetologia 1998; 41: 416-423.10.1007/s001250050924Search in Google Scholar

4. Pop-Busui R. What do we know and we do not know about cardiovascular autonomic neuropathy. J Cardiovasc Transl Res 2012; 5: 463-478.10.1007/s12265-012-9367-6Search in Google Scholar

5. Vinik AI, Maser RE, Mitchell BD et al. Diabetic autonomic neuropathy. Diabetes Care 2003; 26: 1553-1579.10.2337/diacare.26.5.1553Search in Google Scholar

6. Vinik AI, Ziegler D. Diabetic cardiovascular autonomic neuropathy. Circulation 2007; 115: 387-397.10.1161/CIRCULATIONAHA.106.634949Search in Google Scholar

7. Maser RE, Lenhard MJ. Cardiovascular autonomic neuropathy due to diabetes mellitus: clinical manifestations, consequences and treatment. J Clin Endocrinol Metab 2005; 90: 5896-5903.10.1210/jc.2005-0754Search in Google Scholar

8. Freeman R. Autonomic peripheral neuropathy. Lancet 2005; 365: 1259-1270.10.1016/S0140-6736(05)74815-7Search in Google Scholar

9. Rett K. Diabetes Therapy on the Move: Is glucocentric view outdated? In: Rett K [Ed]. Better chances for nerves and vessels, Georg Thieme Verlag KG Stuttgart 2011:1-8.Search in Google Scholar

10. Vlad I, Popa AR. Epidemiology of diabetes mellitus: a current review. Rom J Diabetes Nutr Metab Dis. 2012; 19: 433-44010.2478/v10255-012-0050-0Search in Google Scholar

11. King H, Rewers M. Global estimates for prevalence of diabetes mellitus and impaired glucose tolerance in adults. Diabetes Care 1993;16:157-177.10.2337/diacare.16.1.1578123057Search in Google Scholar

12. Low PA, Tomalia VA. Orthostatic hypotension: mechanisms, causes, management. J Clin Neurol 2015;11:220-22610.3988/jcn.2015.11.3.220450737526174784Search in Google Scholar

13. Lahiri MK, Kannankeril PJ, Goldberger JJ. Assessment of autonomic function in cardiovascular diseas: physiological basis and prognostic implications. J Am Coll Cardiol 2008; 51:1725-1733.10.1016/j.jacc.2008.01.03818452777Search in Google Scholar

14. Ewing DJ, Clarke BF. Diabetic autonomic neuropathy: present insights and future prospects. Diabetes Care 1986; 9: 648-665.10.2337/diacare.9.6.6483100258Search in Google Scholar

15. Pop-Busui R, Evans GW, Gerstein HC et al. Effects of cardiac autonomic dysfunction on mortality risk in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Trial. Diabetes Care 2010; 33:1578-1584.10.2337/dc10-0125289036220215456Search in Google Scholar

16. Fedorowski A, Stavenow L, Hedblad B et al. Orthostatic hypotension predicts all-cause mortality and coronary events in middle-aged individuals. Eur Heart J 2010; 31: 85-91.10.1093/eurheartj/ehp329280091919696189Search in Google Scholar

17. Mancia M, Grassi G. Orthostatic hypotension and cardiovascular risk: defining the epidemiological and prognostic relevance. Eur Heart J 2010; 31: 12-14.10.1093/eurheartj/ehp38919734166Search in Google Scholar

18. Soliman EZ, Elsalam MA, Li Y. The relationship between high resting heart rate and ventricular arrythmogenesis in patients referred to ambulatory 24 h electrocardiographic recording. Europace 2010; 12: 261-265.10.1093/europace/eup34419887457Search in Google Scholar

19. Ewing DJ, Clarke BF. Diagnosis and management of diabetic autonomic neuropathy. Br Med J (Clin Res Ed) 1982; 285:916-918.10.1136/bmj.285.6346.91615000186811067Search in Google Scholar

20. Tesfaye S, Boulton AJ, Dyck PJ et al. Diabetic Neuropathies: update on definitions, diagnostic criteria, estimation of severity, and treatments. Diabetes Care 2010; 33: 2285-2293.10.2337/dc10-1303294517620876709Search in Google Scholar

21. Ewing DJ, Martyn CN, Young RJ et al. The value of cardiovascular autonomic function tests: 10 years experience in diabetes. Diabetes Care 1985; 8:491-498.10.2337/diacare.8.5.4914053936Search in Google Scholar

22. American Academy of Neurology. Assessment: clinical autonomic testing report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 1996; 46:873-880.Search in Google Scholar

23. Spallone V, Morganti R, Fedele T et al. Reappraisal of the diagnostic role of orthostatic hypotension in diabetes. Clin Auton Res 2009; 19: 58-64.10.1007/s10286-009-0517-019199088Search in Google Scholar

24. Pafili K, Trypsianis G, Papzoglou D, Maltezos E, Papanas N. Simplified diagnosis of cardiovascular autonomic neuropathy in type 2 diabetes using Ewing s battery. Rev Diabet Stud. 2015;12(1-2):213-21910.1900/RDS.2015.12.213539799126676669Search in Google Scholar

25. Vinik AI, Maser RE, Ziegler D. Autonomic imbalance: prophet of doom or scope for hope. Diabet Med 2011; 28: 643-651.10.1111/j.1464-5491.2010.03184.x312370521569084Search in Google Scholar

26. Jermendy G, Kempler P, Keresztes K et al. The clinical features and diagnosis of autonomic neuropathy. In: Kempler P, Varkonyi T[Eds]. Neuropathies: A Global Clinical Guide, Zafir Press, Budapest 2012: 69-130.Search in Google Scholar

27. Dimitropoulos G, Tahrani AA, Stevens MJ. Cardiac autonomic neuropathy in patients with diabetes mellitus. World J Diabetes 2014;5(1):17-39.10.4239/wjd.v5.i1.17393242524567799Search in Google Scholar

28. La Rovere M, Maestri R, Pinna G. Baroreflex sensitivity assessment: latest advances and strategies. Eur Cardiol 2011;7(2):89-92.10.15420/ecr.2011.7.2.89Search in Google Scholar

29. Kempler P, Varadi A, Szalay F et al. Autonomic neuropathy and corrected QT interval prolongation. There is a relationship. Diabetes Care 1994; 17: 454-456.10.2337/diacare.17.5.4548062618Search in Google Scholar

30. Schneider CA, Baer FM, Erdmann E. QT-dispersion - analysis and prognostic implications. Dtsch Med Wochenschr 1999; 124:396-402.10.1055/s-2007-102432410226648Search in Google Scholar

31. Ziegler D, Weise F, Langen KJ et al. Effect of glycaemic control on myocardial sympathetic innervation assessed by 123 I-metaiodobenzylguanidine scintigraphy: a 4-year prospective study in IDDM patients. Diabetologia 1998; 41: 443-451.10.1007/s0012500509289562349Search in Google Scholar

32. Kuehl M, Stevens MJ. Cardiovascular autonomic neuropathies as complications of diabetes mellitus. Nat Rev Endocrinol 2012; 8(7):405-41610.1038/nrendo.2012.2122371159Search in Google Scholar

33. Spallone V, Ziegler D, Freeman R et al. Cardiovascular autonomic neuropathy in diabetes: clinical impact, assessment, diagnosis and management. Diabetes Metab Res Rev 2011; 27: 639-65310.1002/dmrr.123921695768Search in Google Scholar

34. Buse JB, Ginsberg HN, Bakris GL et al. Primary prevention of cardiovascular diseases in people with diabetes mellitus: a scientific statement from American Heart Association and the American Diabetes Association. Circulation 2007; 115: 114-126.10.1161/CIRCULATIONAHA.106.17929417192512Search in Google Scholar

35. Pop-Busui R, Low PA, Waberski BH et al. Effects of prior intensive insulin therapy on cardiac autonomic nervous system function in type 1 diabetes mellitus: the Diabetes Control and Complications Trial/ Epidemiology of Diabetes Interventions and Complications study (DCCT/EDIC). Circulation 2009; 119: 2886-2893.10.1161/CIRCULATIONAHA.108.837369275700519470886Search in Google Scholar

36. Pop-Busui R. Cardiac autonomic neuropathy in diabetes: a clinical perspective. Diabetes Care 2010; 2:434-441.10.2337/dc09-1294280929820103559Search in Google Scholar

37. Nathan DM, Genuth S, Lachin J et al. The effect of intensive treatment of diabetes on the development and progression of long-therm complications in insulin-dependent diabetes mellitus. N Engl J Med 1993; 329: 977-986.10.1056/NEJM1993093032914018366922Search in Google Scholar

38. The Diabetes Control and Complications Trial Research Group.The effect of intensive diabetes therapy on the development and progression of neuropathy. Ann Intern Med 1995; 122: 561-568.10.7326/0003-4819-122-8-199504150-000017887548Search in Google Scholar

39. Martin CL, Albers J, Herman WH et al. Neuropathy among diabetes control and complications trial cohort 8 years after trial completion. Diabetes Care 2006; 29: 340-344.10.2337/diacare.29.02.06.dc05-1549262272016443884Search in Google Scholar

40. Pop-Busui R, Herman WH, Feldman EL et al. DDCT and EDIC studies in type 1 diabetes: lessons for diabetic neuropathy regarding metabolic memory and natural history. Curr Diab Rep 2010; 10: 276-282.10.1007/s11892-010-0120-8360867220464532Search in Google Scholar

41. Witte DR, Tesfaye S, Chaturvedi N et al. Risk factors for cardiac autonomic neuropathy in type 1 diabetes mellitus. Diabetologia 2005; 48: 164-171.10.1007/s00125-004-1617-y15619072Search in Google Scholar

42. Brownlee M. Diabetic complications: pathobiology of hyperglycemic damage and potential impact on treatment. In: Thornalley PJ, Kempler P [Eds]. Complications of diabetes mellitus: pathophysiology and pathogenetically-based treatment options, Georg Thieme Verlag KG Stuttgart 2009: 1-8.Search in Google Scholar

43. Hammes HP. Diabetic nerve, vascular and organ damage from the pathogenetic key to new therapeutic approaches. In: Rett K [Ed]. Better chances for nerves and vessels, Georg Thieme Verlag KG Stuttgart 2011: 9-19.Search in Google Scholar

44. Pop Busui R. What do we know and what we do not know about cardiovascular autonomic neuropathy in diabetes. J Cardiovasc Trans Res 2012; 5: 463-478.10.1007/s12265-012-9367-6363456522644723Search in Google Scholar

45. Stratton IM, Adler AI, Neil HA et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000; 321: 405-412.10.1136/bmj.321.7258.4052745410938048Search in Google Scholar

46. Holman RR, Paul SK, Bethel MA et al. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008; 359: 1577-1589.10.1056/NEJMoa0806470Search in Google Scholar

47. Jermendy G. Late effect of treatment for reducing cardiovascular risk-a hypothesis on cardiometabolic therapeutic memory. Med Hypotheses 2009; 73: 73-79.10.1016/j.mehy.2009.01.034Search in Google Scholar

48. Ohkubo Y, Kishikawa H, Araki E, Miyata T et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diabets Res Clin Pract 1995; 28:103-11710.1016/0168-8227(95)01064-KSearch in Google Scholar

49. Azad N, Emanuele NV, Abraira C et al. The effects of intensive glycemic control on neuropathy in the VA Cooperative Study on type II diabetes mellitus. J Diabetes Complications 1999; 13: 307-313.10.1016/S1056-8727(99)00062-8Search in Google Scholar

50. Gaede P, Vedel P, Larsen GV et al. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 2003; 348: 383-393.10.1056/NEJMoa02177812556541Search in Google Scholar

51. Maser RE, Mitchell BD, Vinik AI et al. The association between cardiovascular autonomic neuropathy and mortality in individuals with diabetes: a meta-analysis. Diabetes Care 2003; 26:1895-1901.10.2337/diacare.26.6.189512766130Search in Google Scholar

52. Ziegler D, Zentai CP, Perz S et al. Prediction of mortality using measures of cardiac autonomic dysfunction in the diabetic and nondiabetic population: the MONICA/KORA Augsburg Cohort Study. Diabetes Care 2008; 31: 556-56110.2337/dc07-161518086873Search in Google Scholar

53. Bolli GB, Fanelli CG, Porcellati F et al. Diabetic autonomic neuropathy. Response to hypoglycemia. In: Gries FA, Cameron NE, Low PA, Ziegler D [Eds]. Textbook of diabetic neuropathy, Georg Thieme Verlag, Stuttgart 2003:286-295.Search in Google Scholar

54. Adler GK, Bonyhay I, Failing H et al. Antecedent hypoglycemia impairs autonomic cardiovascular function: implications for rigorous glycemic control. Diabetes 2009; 58: 360-366.10.2337/db08-1153262860919056608Search in Google Scholar

55. Nordin C. The case for hypoglycaemia as a proarrhythmic event: basic and clinical evidence. Diabetologia 2010; 53: 1552-1561.10.1007/s00125-010-1752-620407743Search in Google Scholar

56. Stephenson JM, Kempler P, Perin PC et al. Is autonomic neuropathy a risk factor for severe hypoglycaemia? The EURODIAB IDDM Complications Study. Diabetologia 1996; 39: 1372-1376.10.1007/s0012500505858933007Search in Google Scholar

57. Meyer C, Grossman R, Mitrakou A et al. Effects of autonomic neuropathy on counterregulation and awareness of hypoglycemia in type 1 diabetic patients. Diabetes Care 1998; 21:1960-1966.10.2337/diacare.21.11.19609802751Search in Google Scholar

58. Gerstein HC, Miller ME, Byintgton RP et al. Effects of intensive glucose lowering in type 2 diabetes. New Engl J Med 2008; 358: 2545-2559.10.1056/NEJMoa0802743455139218539917Search in Google Scholar

59. Gerstein HC, Riddle MC, Kendall DM et al. Glycemia treatment strategies in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. Am J Cardiol 2007; 99: 34-43.10.1016/j.amjcard.2007.03.00417599423Search in Google Scholar

60. Calles-Escandon J, Lovato LC, Simons-Morton DG et al. Effect of intensive compared with standard glycemia treatment strategies on mortality by baseline subgroup characteristics: the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. Diabetes Care 2010; 33: 721-727.10.2337/dc09-1471284501220103550Search in Google Scholar

61. Skyler JS, Bergenstal R, Bonow RO et al. Intensive glycemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE and VA Diabetes Trials: a position statement of the American Diabetes Association and a scientific statement of the American College of Cardiology Foundation and the American Heart Association. Diabetes Care 2009; 32:187-192.10.2337/dc08-9026260681219092168Search in Google Scholar

62. Vinik AI, Maser RE, Ziegler D. Neuropathy: the crystall ball for cardiovascular disease. Diabetes Care 2010; 33: 1688-1690.10.2337/dc10-0745289038220587730Search in Google Scholar

63. Vinik AI. The conductor of the autonomic orchestra. Frontiers in Endocrinology 2012; ID 103389.10.3389/fendo.2012.00071338037622737143Search in Google Scholar

64. Palatini P, Benetos A, Grassi G et al. Identification and management of the hypertensive patient with elevated heart rate: statement of a European Society of Hypertension Consensus Meeting. J Hypertens 2006; 24: 603-610.10.1097/01.hjh.0000217838.49842.1e16531784Search in Google Scholar

65. Kadoi Y. Anesthetic considerations in diabetic patients. Part I: preoperative considerations of patients with diabetes mellitus. J Anesth 2010; 24: 739-747.10.1007/s00540-010-0987-120640453Search in Google Scholar

66. Young LH, Wackers FJ, Chyun DA et al. Cardiac outcomes after screening for asymptomatic coronary artery disease in patients with type 2 diabetes: the DIAD study: a randomized controlled trial. JAMA 2009; 301:1547-1555.10.1001/jama.2009.476289533219366774Search in Google Scholar

67. Maser RE, Mitchell BD, Vinik AI et al. The association between cardiovascular autonomic neuropathy and mortality in individuals with diabetes: a meta-analysis. Diabetes Care 2003; 26:1895-1901.10.2337/diacare.26.6.189512766130Search in Google Scholar

68. Dinh W, Futh R, Lankisch M et al. Cardiovascular autonomic neuropathy contributes to left ventricular diastolic dysfunction in subjects with type 2 diabetes and impaired glucose tolerance undergoing coronary angiography. Diabet Med 2011; 28: 311-318.Search in Google Scholar

69. Brotman DJ, Bash LD, Qayyum R et al. Heart rate variability predicts ESRD and CKD-related hospitalization. J Am Soc Nephrol 2010; 21: 1560-1570.10.1681/ASN.2009111112301352420616169Search in Google Scholar

70. Valensi P, Cosson E. It is not yet the time to stop screening diabetic patients for silent myocardial ischaemia. Diabetes Metab 2010; 36: 91-96.10.1016/j.diabet.2010.01.00120189425Search in Google Scholar